P/E ratio for XBiotech (XBIT)
P/E ratio as of April 2025 (TTM): -2.88
According to XBiotech's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.87766. At the end of 2022 the company had a P/E ratio of -3.25.
P/E ratio history for XBiotech from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.25 | -83.06% |
| 2021 | -19.2 | -52.13% |
| 2020 | -40.1 | -3787.75% |
| 2019 | 1.09 | -112.41% |
| 2018 | -8.76 | 120.08% |
| 2017 | -3.98 | -35.9% |
| 2016 | -6.21 | -32.27% |
| 2015 | -9.17 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -0.3090 | -89.26% | 🇺🇸 USA |
 | 0.0000 | -100.00% | 🇺🇸 USA |
 | -2.31 | -19.56% | 🇳🇱 Netherlands |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.